<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E5A82D2C-5AD4-488A-ACFF-566345A5D6DA"><gtr:id>E5A82D2C-5AD4-488A-ACFF-566345A5D6DA</gtr:id><gtr:name>Heriot-Watt University</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Riccarton</gtr:line2><gtr:line3>Ricarton</gtr:line3><gtr:line4>Currie</gtr:line4><gtr:postCode>EH14 4AS</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D22E0411-DAEE-4300-B3DF-6860DB4826C1"><gtr:id>D22E0411-DAEE-4300-B3DF-6860DB4826C1</gtr:id><gtr:name>Funky Fone Sox Company</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DD711A49-49C1-4D63-966F-D4313B1C5F37"><gtr:id>DD711A49-49C1-4D63-966F-D4313B1C5F37</gtr:id><gtr:name>Aquila Histoplex</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/67ABD4F2-1AB0-483C-9F74-C6E9B0460BF9"><gtr:id>67ABD4F2-1AB0-483C-9F74-C6E9B0460BF9</gtr:id><gtr:name>NHS Lothian</gtr:name><gtr:address><gtr:line1>Royal Victoria Hospital</gtr:line1><gtr:line2>13 Craigleith Road</gtr:line2><gtr:postCode>EH4 2DN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Royal (Dick) School of Veterinary Scienc</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E5A82D2C-5AD4-488A-ACFF-566345A5D6DA"><gtr:id>E5A82D2C-5AD4-488A-ACFF-566345A5D6DA</gtr:id><gtr:name>Heriot-Watt University</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Riccarton</gtr:line2><gtr:line3>Ricarton</gtr:line3><gtr:line4>Currie</gtr:line4><gtr:postCode>EH14 4AS</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D22E0411-DAEE-4300-B3DF-6860DB4826C1"><gtr:id>D22E0411-DAEE-4300-B3DF-6860DB4826C1</gtr:id><gtr:name>Funky Fone Sox Company</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DD711A49-49C1-4D63-966F-D4313B1C5F37"><gtr:id>DD711A49-49C1-4D63-966F-D4313B1C5F37</gtr:id><gtr:name>Aquila Histoplex</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/67ABD4F2-1AB0-483C-9F74-C6E9B0460BF9"><gtr:id>67ABD4F2-1AB0-483C-9F74-C6E9B0460BF9</gtr:id><gtr:name>NHS Lothian</gtr:name><gtr:address><gtr:line1>Royal Victoria Hospital</gtr:line1><gtr:line2>13 Craigleith Road</gtr:line2><gtr:postCode>EH4 2DN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4A9E1FC3-1237-4AE1-8A3F-9633FDA1FFC6"><gtr:id>4A9E1FC3-1237-4AE1-8A3F-9633FDA1FFC6</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Savill</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/43624727-2D66-49AE-8923-426DD4CDD141"><gtr:id>43624727-2D66-49AE-8923-426DD4CDD141</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Seckl</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700000"><gtr:id>78645077-E8A8-4CBA-BD1D-2A59CBF6C919</gtr:id><gtr:title>Translational Entrepreneur</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700000</gtr:grantReference><gtr:abstractText>The University of Edinburgh and the MRC are piloting a new approach to take Edinburgh s world-leading medical science and translate this into direct benefits for patients and the local and wider community. Both commercial and non-commercial benefits are to be supported.</gtr:abstractText><gtr:technicalSummary>The University of Edinburgh s College of Medicine and Veterinary Medicine, exploiting a longstanding focus on interdisciplinary research, wishes funding in part support of a pilot project to test the concept of a Translational Entrepreneur to galvanise a step-change in translation of our world-leading biomedical science (14th in World, 5th in Europe, THES, Nov 2005) into improvements in human (and animal) health.</gtr:technicalSummary><gtr:fund><gtr:end>2010-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>273709</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>NHS Lothian</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>NHS Lothian</gtr:description><gtr:id>9ED06294-6E14-479A-A5FB-6DE991F610EB</gtr:id><gtr:impact>With NHS Lothian, the Entrepreneur set up a parallel system to the one he ran in the University. This is now formally part of the Edinburgh BioQuarter. NHS Lothian have paid for a post, a Business dev exec, to follow mentoring through the EiR and bus. dev manager and adopt the process of working with PIs to address unmet needs by developing imaginative yet milestone driven projects &amp;amp; programmes, building teams, taking advantage of industry contacts and delivering products and services that meet these unmet needs. The associate continues to build translational projects with one not for profit company formed ipSOX www.ipsox.co.uk by 2 nurses and a consultant from the metabolic unit to provide bespoke covers for insulin pumps. ipSOX has been formed from NHS Lothian and Napier University and collaborates extensively with a UK company on design and manufacture of covers that already are achieving exports and significant orders through users and manufactures. We are using this company to train an intern, who is delivering new media communication as part of diabetes month with &amp;quot;memorable diabetes momments&amp;quot; to expand marketing reach. This is an example of harnessing enthusiastic professionals into a non conventional translational delivery approach that has alrady donated to diabetes research and is building new products for pump users and will shortly be applying profits to fund insulin pump research applications. The brand is being transferred to a company producing insulin pen covers http://pentrim.com/ who will continue the supply to customers, donating profits to JDRF and developing the sports range. 
The Business Development Executive continues to build multiple translational projects for the NHS and has accessed valuable sources of funds to provide catalytic investment into projects.</gtr:impact><gtr:outcomeId>0E1F32686D5-1</gtr:outcomeId><gtr:partnerContribution>Funding of an Enterprise Associate position to work with the Translational Entrepreneur and team towards extending our area of operation to build understanding, help culture change and deliver commercial outputs for NHS Lothian</gtr:partnerContribution><gtr:piContribution>We are building on the model developed by the Translational Entrepreneur appointment with the College of Medicine &amp;amp; Vet Medicine, working in collaboration to enhance technology transfer from University of Edinburgh and NHS Lothian</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Aquila Histoplex</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Aquila BioMedical -Histoplex LLP</gtr:description><gtr:id>918F88AD-7058-4899-B54B-DF0A339622B9</gtr:id><gtr:impact>support of Aquila services in autoimmune disease, immuno-oncology through testing of histology samples from model systems and the clinic, and income generation. This LLP has been successful for Aquila and Histoplex team that the LLP will be dissolved early 2017 and will formally become a division of the profitable global company.</gtr:impact><gtr:outcomeId>5458ea50b8fc82.97111985-1</gtr:outcomeId><gtr:partnerContribution>LLP with an University team providing advanced histology testing including the first UK accredited RNAscope service.</gtr:partnerContribution><gtr:piContribution>The mechanism of action company Aquila Biomedical provides an established CRO laboratory and an expanding set of clients</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Funky Fone Sox Company</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ipSOX Funky Fone Sox</gtr:description><gtr:id>B13D6A03-E7F7-43B1-B0A9-B4AEF6BCAB23</gtr:id><gtr:impact>Donations made to Diabetes UK</gtr:impact><gtr:outcomeId>5457b7ba763ac7.25399269-1</gtr:outcomeId><gtr:partnerContribution>Funky Fone Sox organised the manufacturing of the ipSOX insulin pump covers at no added cost</gtr:partnerContribution><gtr:piContribution>The ipSOX team designed the products to be manufactured</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Heriot-Watt University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Engineering &amp; Physical Sciences</gtr:department><gtr:description>Edinburgh Partners Devices and Diagnostics</gtr:description><gtr:id>68903A7E-4BBA-4BF9-BE14-B83FB82F576D</gtr:id><gtr:impact>The outputs are listed under MC_PC_12014
We have expanded the collaboration beyond the funded projects in MC_PC_12014 into a project on birthing mirror and a histology water bath. 
We have combined with Heriot Watt to bring together a further CiC application in October 2014</gtr:impact><gtr:outcomeId>JZrMGGpWSy1-1</gtr:outcomeId><gtr:partnerContribution>Heriot Watt brings proven engineering and fabrication skills/ capabilities applied to medical devices</gtr:partnerContribution><gtr:piContribution>University of Edinburgh led a collaboration with Heriot-Watt that includes Confidence in Concept funding covering Devices Diagnostics and Diagnostics Apps for hand help devices. Edinburgh brings the medical and unmet need and computing aspects through School of Informatics.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Fibromed with Institute of Cancer Research</gtr:description><gtr:id>94BB4DD0-AEA7-4602-9B52-540A16B1C6E5</gtr:id><gtr:impact>Data on optimisation of the product</gtr:impact><gtr:outcomeId>5457b5b6e16f99.79864343-1</gtr:outcomeId><gtr:partnerContribution>The pharmacology group are characterising the performance of these cells against the gold standard primary human hepatocytes</gtr:partnerContribution><gtr:piContribution>Scientists are providing stem cell hepatocytes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Commercialisation seminar</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4F792C9B-6353-44AF-9A58-E75A08DD359F</gtr:id><gtr:impact>Presented in seminar on commercialisation Division of Pathway Medicine University of Edinburgh

Interest in translational activity. Measured by two subsequent DPFS Portfolio applications</gtr:impact><gtr:outcomeId>527785B5AD9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Globalscot Meeting New York</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4A0F8563-6990-45B0-95EE-BA08C6064AD4</gtr:id><gtr:impact>Workshop on Scottish Life Science at globalscot meeting New York. December 2007.

Recognition of opportunity and issues by this influential group</gtr:impact><gtr:outcomeId>5BEBAF1AF83</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UNICO</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>901E3882-883A-4E10-9011-A2E23E9FE6C8</gtr:id><gtr:impact>Entrepreneurs in residence: strangers in our midst? UNICO CONFERENCE Nottingham - 5-7 December 2007

Continued support from Scottish Enterprise</gtr:impact><gtr:outcomeId>10DD74F3988</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference For Generation Scotland</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>263B904B-C75C-4C56-A2D3-CE3E0EC1C1C3</gtr:id><gtr:impact>Academic and Pharma executive exploring how to use biobanks

continued engagement on use of Generation Scotland for generation of specific iPS lines for toxicity testing</gtr:impact><gtr:outcomeId>m2DEwdM9Y8U</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BIO International US meeting - BIO Partnering</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FD339AF9-1C2B-49F7-8968-79FFEFDEAAE1</gtr:id><gtr:impact>Business Partnering Forum for Pharma / Biotech and CROs. Seeking opportunities for company propositions.

Potential future clients for BioQuarter development. Potential future company partners .</gtr:impact><gtr:outcomeId>7048EA76818</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Commercialisation Seminar</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A6A961E3-265B-4542-8CB4-5C7B26DEB1D6</gtr:id><gtr:impact>The entrepreneur in residence and effect on spin-out activity. Proof of Concept Programme Symposium on creating high value spin-outs: Glasgow

Connections made to senior business and academic colleagues</gtr:impact><gtr:outcomeId>84D4A3C922F</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Judge on Venture Competition</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8F7C6A9B-389B-4CEC-BC86-5F110EB4789F</gtr:id><gtr:impact>Finals of Dundee Students Venture competition. Presentations questions and award

Trias Gkikopoulos has been named the winner of the University of Dundee's Venture 2013 competition for his business idea of designing and building an unmanned aircraft for civil, commercial and scientific use. National press.</gtr:impact><gtr:outcomeId>r2DPMYtXDcJ</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.dundee.ac.uk/pressreleases/2013/march13/ventureprize.htm</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BioDundee conference 2010 -chair of panel on Building Alliances</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1ECAF96A-2CCF-47D5-94A0-62AC38FA966B</gtr:id><gtr:impact>chair of panel that focused on partnerships and collaborations within the life science sector. event focused on science-business community including life science entrepreneurs

engagement of VC interest for bioQUarter, alliance forged with inward investment company for new venture, partnerships for translational programmes in NHS and the University</gtr:impact><gtr:outcomeId>RrJRo8yraGv</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Judge on Venture Competition</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8B509F7D-444D-4A6D-A9B1-EDA61C8CFB7E</gtr:id><gtr:impact>Finals of Dundee Students Venture competition to award &amp;pound;10,000 in prize money

continue to engage with the Design aid+ team on accessories for junior doctors</gtr:impact><gtr:outcomeId>bw2PPEdSYQx</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BIO business - Geneva 2008</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B0842114-2CD7-42FE-8E36-3D498C0C976E</gtr:id><gtr:impact>Platform shared with Roche on innovative company spin-out plans for a CNS company.

none yet</gtr:impact><gtr:outcomeId>38354FD71ED</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Investor Meeting Fibromed</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>97883104-6D2B-4F81-A5EC-B38C0CB71B05</gtr:id><gtr:impact>Approximately 50 investors were present for the event. Engagement with 2 investors was initiated.

Fibromed was invited to present at BioTrinity 2012</gtr:impact><gtr:outcomeId>Y8SUz1cEqib</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Globalscot Meeting Hong Kong</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>80811905-1BA9-4BEC-88CF-8735E1C4861D</gtr:id><gtr:impact>Presentation on Scottish Life Science at globalscot meeting Hong Kong. December 2008

meeting with influential international business people and investors, initiated concept of incubator fund</gtr:impact><gtr:outcomeId>0C237F23380</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Conference Panel</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DD6B7B44-8334-4AF1-8D13-F7F8205E25BA</gtr:id><gtr:impact>Mixed audience of Pharma and Biotech executives -who engaged in the discussion on the changes in the drug development industry and how to best access expertise from accademia

Follow up with several companies</gtr:impact><gtr:outcomeId>cTs1xKBSS1k</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Medical Training on Pharmaceutical Product Development</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2464925B-C1C8-4202-B193-41A332635D59</gtr:id><gtr:impact>Invited speaker to put the drug industry in context

Engagement from a Glasgow Doctor on commercial options</gtr:impact><gtr:outcomeId>igNoStb8YCy</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Biotrinity Investor conference Fibromed</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F9BB0A74-393C-4E50-867A-54C042BD98D3</gtr:id><gtr:impact>One of UK largest investor conferences, presenting to more than 100 investors.

Engagement with investors and Pharma executives</gtr:impact><gtr:outcomeId>kMKHQm1wC1q</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>High Growth Unit (Fibromed Products)</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>78C74D28-38C0-40A5-9DE1-2A55B394804B</gtr:id><gtr:outcomeId>V6aE7onr7WB</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Innovation Grant (FibromedProducts)</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>EB46BDE4-B794-406A-831E-D147A182D87B</gtr:id><gtr:outcomeId>KziTYvsoQNb</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LSBAS support of in vivo venture</gtr:description><gtr:end>2008-11-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>711100C1-4184-45E5-97F4-20FF4C9D2614</gtr:id><gtr:outcomeId>398BB5766080</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Generation Scottland Resource Access Fibromed Ltd</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>AE035584-B3B1-4440-AE63-F914986E3FC1</gtr:id><gtr:outcomeId>cjrVoxnHVTJ0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>19370</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Edinburgh BioQuarter Fibromed validation</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:fundingRef>GQ2630</gtr:fundingRef><gtr:id>DBF94BA7-E2A7-431C-9F96-11249D161C74</gtr:id><gtr:outcomeId>frPEf6ppPiV</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Edinburgh BioQuarter Funding/Edinburgh bioQuarter</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>University of Edinburgh</gtr:fundingOrg><gtr:id>5C792C21-0A25-4F92-9F39-816ADE626009</gtr:id><gtr:outcomeId>gX7FDCUEo7t0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Tool Box for MHRA submission</gtr:description><gtr:end>2008-12-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>3E6DC749-0C7B-44EB-9560-F128EC282019</gtr:id><gtr:outcomeId>02DAC5FDB4E0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Neuropathic pain trial agent production</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>NHS Lothian</gtr:fundingOrg><gtr:id>B32DF1A5-C1D3-40C3-8B95-EA03D88DD507</gtr:id><gtr:outcomeId>AMqugWh5Ygu</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Moray Trust</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Moray Council</gtr:fundingOrg><gtr:id>65EB4E1E-E9D7-492B-A373-A01D4F623A94</gtr:id><gtr:outcomeId>58c6bf049c9108.73037273</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>8250</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Interim Management Support Fibromed</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>09AC0FE1-42D0-490B-BCCB-C301921486B7</gtr:id><gtr:outcomeId>tYEnEjtLiEN</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Graduate Internship Aquila BioMedical</gtr:description><gtr:end>2014-02-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>0801FD79-BCD0-4F0A-A1D2-03AF10747A2D</gtr:id><gtr:outcomeId>sXjP5AKHKh2</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Edinburgh BioQuarter Aquila Biomedical market</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:fundingRef>GQ2514</gtr:fundingRef><gtr:id>25A6D440-B355-4C5F-B268-1F8CEDE04494</gtr:id><gtr:outcomeId>iThce43ufzX</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>Belgium, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Galapagos Edinburgh Cancer Discovery Unit</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Galapagos Genomics</gtr:fundingOrg><gtr:id>06B12320-59A3-45A8-A253-E4C86ADFF259</gtr:id><gtr:outcomeId>Qs2tMghH7KT</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proof of Concept (TRPM8)</gtr:description><gtr:end>2009-10-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>D31A2D94-5699-4B14-8D87-91F9089CD899</gtr:id><gtr:outcomeId>09E20E50A690</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2007-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Investor Ready Grant Aquila Biomedical</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>FCC907B9-883C-4127-B6C5-90C17F2236B2</gtr:id><gtr:outcomeId>HaGsE1j1MgE</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Marketing Grant Aquila Biomedical</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>569FE292-EFDA-4C8B-94EE-42D1D24D888F</gtr:id><gtr:outcomeId>gQoB1LWx2og</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LSBAS support of diagnostic venture</gtr:description><gtr:end>2008-09-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>2B758109-5464-4D00-9B98-66BFEDA54D9C</gtr:id><gtr:outcomeId>250921252F30</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Graduate Internship Aquila Biomedical</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>C653B7DD-5BFE-4C5D-9A4D-0F65D6D7CE55</gtr:id><gtr:outcomeId>ijekZ3HeUXH</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SMART Aquila BioMedial</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>1F00AB3A-AE80-43CD-8055-858AFFDC9693</gtr:id><gtr:outcomeId>VHdAftjgWVA</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>36000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European Regional Development Fund (ERDF)</gtr:department><gtr:description>Executive Director Designate Fibromed CBO</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>B8D8AFC1-B703-44AE-85F6-820958DC997A</gtr:id><gtr:outcomeId>eAfWw5ABeMB</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Scottish Universities Life Sciences Alliance (SULSA)</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>Scottish Universities Life Sciences Alliance (SULSA)</gtr:fundingOrg><gtr:id>EFA2358F-90DA-4A93-9CA5-D721C25E575F</gtr:id><gtr:outcomeId>6E81EF4CD7C0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Investment in NeurocentRx Ltd</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Equity Gap</gtr:fundingOrg><gtr:id>2DB9D0AA-4A99-45D9-A3E9-22F7BFD291B1</gtr:id><gtr:outcomeId>5457b3db0156d6.92005582</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>16000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Innovation Grant Pain Models Aquila</gtr:description><gtr:end>2013-01-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>BD004A03-9BEB-4075-A93D-22DE5C269190</gtr:id><gtr:outcomeId>Vw81TA7KXfh</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>14000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>undergraduate placement programme (Aquila BioMedical)</gtr:description><gtr:end>2022-07-02</gtr:end><gtr:fundingOrg>Scottish Universities Life Sciences Alliance (SULSA)</gtr:fundingOrg><gtr:id>50EDA228-F700-4D46-8709-9E2E3E8294EE</gtr:id><gtr:outcomeId>B95FeWNZU4z</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>International Manager for Hire Aquila Biomedical</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>BCE0D442-F7A7-49B4-86E5-5FC19FFC0C2F</gtr:id><gtr:outcomeId>ULAPC2edMWu</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>230000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Aquila Biomedical (Regional Selective Assistance)</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Scottish Government</gtr:fundingOrg><gtr:id>8C4A8FF5-A9A7-40A5-A39F-D4D402BCB44A</gtr:id><gtr:outcomeId>58ad63076a6ba3.09951602</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NC3R MRC DPFS (Functional Optical Imaging in mice and man)</gtr:description><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>B6855201-ED93-420F-B916-31DADB4F5A0B</gtr:id><gtr:outcomeId>545a7646abc876.05835222</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Investment (Neurocentrx Pharma)</gtr:description><gtr:end>2020-01-02</gtr:end><gtr:fundingOrg>Neurocentrx Pharma</gtr:fundingOrg><gtr:id>1DF6C639-3EA5-41E8-A156-63F559C0CC05</gtr:id><gtr:outcomeId>56dea675a2c1c4.19935816</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Developmental Pathway Funding Scheme (DPFS)</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>08CE0062-5360-4B48-A665-EC3E1D9EB60F</gtr:id><gtr:outcomeId>3C439341E6D0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>67000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BioSKAPE (Fibromed)</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>6DC7A7B8-669A-48CD-AAE7-55C64D3BDC19</gtr:id><gtr:outcomeId>Lhb6tuV2WZN</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>36000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Executive Director Designate NeurocentRx Pharma MD</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>8C6E3126-F7D8-44F8-BEA4-9582DAFCE923</gtr:id><gtr:outcomeId>NuLk3SvAMzs</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>22848</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BioQuarter ESCF fund NeurocentRx Pharma proposition support</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>659AECAB-997E-4405-B867-EDABC66A9FE8</gtr:id><gtr:outcomeId>CJqaLKMi5p6</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Proof of Concept support of psychiatry patents</gtr:description><gtr:end>2008-12-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>DD72B31E-6306-4C4F-A2EB-7B2C0A61C051</gtr:id><gtr:outcomeId>2DA469464560</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Graduate Internship Aquila Biomedical</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>A3F0C218-091C-4FEE-ADCA-1575F99A03D5</gtr:id><gtr:outcomeId>qvizNd7rghK0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>36000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European Regional Development Fund (ERDF)</gtr:department><gtr:description>Executive Director Designate ERDF Aquila Biomedical</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>F6B0FEFC-20BA-413E-AFFF-9A784951D4DC</gtr:id><gtr:outcomeId>KJde87HPpLe0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SMART Aquila Biomedical</gtr:description><gtr:end>2012-03-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:id>DE0DF3B4-50A6-4ECE-991D-DDBCBD001A96</gtr:id><gtr:outcomeId>MD2RkkSgYFM0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>700000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Confidence in Concept</gtr:description><gtr:end>2014-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>17A8FEFE-4B73-42BF-868A-E5FA21ADB771</gtr:id><gtr:outcomeId>TLn199ZDCGu</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>36000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>European Regional Development Fund (ERDF)</gtr:department><gtr:description>Executive Director Designate Fibromed CEO</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>3E99F9BB-0ED4-4997-9CA1-18691E40032F</gtr:id><gtr:outcomeId>ioKEKAPVrPP</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Initiating knowledge transfer (IKT) Edinburgh research &amp;amp; innovation/Edinburgh Research &amp;amp; Innovation</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>University of Edinburgh</gtr:fundingOrg><gtr:id>34195173-9DDF-44A1-BCE8-49572A7DAF07</gtr:id><gtr:outcomeId>hpRFBiqVTfB0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>MBP-Tracker technology allows us to specifically follow those T cells that drive pathology, quantify them in different organs (including the CNS) and to measure the activation of a range of key disease-associated functions within these T cells</gtr:description><gtr:grantRef>G0700000</gtr:grantRef><gtr:id>88E2221A-6B26-4636-9CAD-1303D8B9D68E</gtr:id><gtr:impact>Aquila BioMedical is using the technology in industrial collaborations on multiple sclerosis drug discovery projects</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>fEFyL1z1MHE</gtr:outcomeId><gtr:protection>Protection not required</gtr:protection><gtr:title>MBP Tracker Mouse</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Business in the Parliament Conference-Scotland</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2C770D75-7853-435B-A0FA-348E0FA5F882</gtr:id><gtr:outcomeId>5BEA05DAD6B</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Holyrood Expert panel in life science business to Scottish Executive</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>94CC02B5-CC54-403F-BB9E-3D2C7021E827</gtr:id><gtr:outcomeId>cmr1BETQBDS</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Meeting with Governor Bank England</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6F2F3E6C-E112-434D-8F98-3DA55BCFD32C</gtr:id><gtr:impact>Key discussion around bank finance. Clear changes in Government approach to SME lending.</gtr:impact><gtr:outcomeId>RX5JSvbUk2N</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Economy Committee Scottish Parliment</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E19FCC3F-37F8-4D5B-AEF7-9A59CEF84CD9</gtr:id><gtr:outcomeId>404F64BDE08</gtr:outcomeId><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>LiSAB ( life science advisory board )</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>7722DB70-7466-4443-A962-F3DF9FF47E94</gtr:id><gtr:impact>LiSAB is a joint industry, enterprise and government strategy team that plays a crucial role in ensuring Scotland has the best possible environment for fledgling technologies and established players alike. It fosters support and discussion between key players in the life sciences sector and those responsible for government policy-making at the very highest level.

LiSAB has a very active remit; to develop and drive overall life sciences strategy in Scotland; developing an environment where ingenuity and innovation can create jobs and wealth for Scotland, as well as genuine benefits for the global community.</gtr:impact><gtr:outcomeId>gyRwcYEgLM7</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>A company based on a combination of stem cell science ( hepatocytes generated through iPS) and a novel polymer support (for differentiation &amp;amp; growth) to be used as a screening tool for pharma in selecting against hERG channel activators, metabolic breakdown products, or patients likely to adversely react in trials. Once hepatocyte established, Fibromed may develop complementary areas (eg: cardiomyocyte screening).</gtr:description><gtr:id>D98310A5-DCFA-458C-9C82-198A09EF1AA9</gtr:id><gtr:impact>Company has been formed (fibromed.co.uk) with 3 leading accademics and HM. Biobank of phenotyped and genotyped cells for iPS development is under construction working with hospitals and Generation Scotland biobank. Hepatocytes are being validate by industry collaborations. Two Executives are retained under HGU funding</gtr:impact><gtr:outcomeId>VM6a8qFJHQL</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Fibromed Products</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:url>http://www.fibromed.co.uk</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>This opportunity is being developed under our new line of activity with the NHS and our BDE appointed, now 3 year in post. Speckled computing has telehealth applications in movement based monitoring in the home and in ITUs or wards. This is a multi healthcare application based technology involving major multidisciplinary teams. Our BDE with translator guidance runs teams that cross medicine, infomatics and support services (edinburgh clinical trials and statistics) as well as company collaborators. There are at least 4 applications. Two (COPD and post operative care) are teams actively seeking funds ( HICF - through to round 2) and pertners. Phillips and Tunstall are connections made through the MRC translator. The Tunstall collaboration is part of a 1.5m HICF application presently through to round 2 assessment.</gtr:description><gtr:id>F56A3256-C794-488E-B396-2FD20188B633</gtr:id><gtr:impact>notable company collaborations and multiple funding applications. Too early for health impact.</gtr:impact><gtr:outcomeId>HutoaaaVM1z</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Speckled Computing - solutions for e-health</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>we are developing a reformulation of an existing drug used as currently as an adjuvant treatment for chronic neuropathic pain experienced by cancer patients. A phase III is currently running with an oral capsule formulation. Currently in paractive this drug is taken intramuscularly or in liquid oral form.</gtr:description><gtr:id>8427E50D-5B3C-4CE2-A320-0FF64D10AA93</gtr:id><gtr:impact>We seek to develop this first as a special and later in other more refined oral liquid capsules rather than the loose filled powder capsule currently in trial. This could bring revenue to the University and a spin out company and encourage other clinicians to think about IP that is contained within their studies. This type of IP is not typically developed by institutes, as it would be pre-selected against due to the development work required and it's non patentable nature.</gtr:impact><gtr:outcomeId>n6VkktHrZqH</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>chronic pain treatment 2</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>this is a laptop based test for AD based on dual task responses and their interpretation. The algorithms have been refined based on over 30 years research (Bob Logie, de laSalla) . We have aligned with Toshiba to help us in the future access worldwide markets. At present we are seeking funds to further validate and refine the test in ongoing large clinical trials.</gtr:description><gtr:id>55EA82A7-10C6-447E-9AE4-75CBF47CE62D</gtr:id><gtr:impact>This will be commercialised for sale in the US and EU, have revenues generated for the University and funders ( along with normal T&amp;amp;Cs).</gtr:impact><gtr:outcomeId>XNKWuEqJNTN</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Cognition product 1 - AD test</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>This opportunity is being developed under our new line of activity with the NHS and our BDE appointed, now 1 year as an FTE. Development of NHS resources from a testing (receivership) based model to an organisation capable of capitalising on its inherent assets (strategic &amp;amp; proactive, business orientated) - particularly it's combination of speed and expertise to develop new assays for disease (worldwide flu variants good example), and its expertise in pathology. Two approaches are being developed. One is an extension of core services. Second is a vehicle through which the NHS can build strategic alliances through Translator connections to companies (eg: Sequenom and HistoRx) and expertise (eg: Prof Chris Price)</gtr:description><gtr:id>9D893E0E-23A4-4F33-BEDE-A79D334C0E5C</gtr:id><gtr:impact>impact to be realised. Process too early at present. Hope to be first EU site for novel genetic tests for selection of patients for wet MD. Further tests under discussion with major US molecular analysis innovator.</gtr:impact><gtr:outcomeId>sBkfVqyD6Br</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>Clinical Lab services</gtr:title><gtr:type>Management of Diseases and Conditions</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Agonist for TRPM8 as topical treatment for chronic pain funded by SE POC.
New funding warded for 6 month chemistry programme from Edinburgh bioQuarter - bridge funding for continuation and talent retention. Now complete 2010. New funding for full team July 2010 from MRC pilot portfolio award. In progress through to end in 2011</gtr:description><gtr:id>7D1BAFBC-DC72-4A72-B607-729D4C730F9A</gtr:id><gtr:impact>in advanced discussion with Pharma</gtr:impact><gtr:outcomeId>2AB15E5688C</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>chronic pain treatment</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Under development through our extension to NHS with appointed BDE now 3 year in post. Concept to capitalise on collective imaging capabilities in various areas ( neuroscience, heart, lung) into a clinical services company. Currently academics do a level of service work that is beneficial though eats time and is not capitalised on fully by the University/NHS. Using the translator's connections to build business team and generate a company. This is an outcome that the clinicians have asked for help in developing. A company vehicle will improve revenue directly back to the core facility that already does a level of contract work with industry but loses its income to a broad University pot. With a business/sales team we expect to increase hugely demand and exposure and hire dedicated staff. The University will benefit from this exposure but also directly financially through consultancy arrangements and as a shareholder.</gtr:description><gtr:id>57B15638-6544-4B7E-82E7-C65D6520E423</gtr:id><gtr:impact>was developed as consultancy</gtr:impact><gtr:outcomeId>eUxU9Ridwnt</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>Clinical Imaging Services venture</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>This opportunity has been developed under our activity with the NHS and our BDE appointed, now 2 year in as mentioned in 'collaborations' section. We are developing a soft, flexible cover for diabetes monitors to suit patients needs. We are doing this with a company called ' Funky phone Sox'. We have established a NFP to deal with proceeds that will be donated back to the Metabolic Unit in Edinburgh</gtr:description><gtr:id>8E1EE29D-DA48-43FC-9EA0-8967357965B5</gtr:id><gtr:impact>A good example of how an unmet need that patients and staff have identified is being translated to a product through with NHS savings through innovation can be realised, with determination on development and imagination on proposing a NFP. This is also an example of an opportunity that despite being valuable and with a significant element of 'culture change' attached to the outcome, might otherwise not be developed as it does not fit with typical TTO metrics (eg: disclosure, patent, licensable). Translator connections include materials experts to adapt current form and media and governance support.</gtr:impact><gtr:outcomeId>iMBeKJYYC5B</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>Insulin pump holder</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:url>http://www.ipsox.co.uk</gtr:url><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Aquila biomedical was incorporated as a company late 2011. Aquila is a preclinical services venture specilaising in turning high-end biological assays (assays based on advanced molecular understanding of disease processes) into screening tools for drug candidate selection. We started in MS with novel MOA models for demyelination and remyelination. The company has expanded more broadly in autoimmunity added pain including cancer pain. Plan to move to other areas - cancer and inflammation and human cell models. This venture has broad support in the University. Now established, it is providing a mechanism for efficient use of many academic assets that are currently underutilised for commercial purposes. The business team has been built and investment obtained and now the company is fully operation and in addition to offering services is building new MOA models.</gtr:description><gtr:id>24A15AA2-DE22-4D8D-8FA4-CB80C8F8FC21</gtr:id><gtr:impact>Company formed, 2x SMART award recieved and 3 employees actively validating models in auto immune MS and pain. aquila-bm.com Now building MS in a dish model with license of specialist mouse line from DKFZ</gtr:impact><gtr:outcomeId>oP1q9GPk4gp</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Aquila Biomedical venture</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:url>http://www.aquila-bm.com</gtr:url><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>An open label study with a well known and available compound has been completed. The study looked at a variety of cancer drug induced pain patients and their response. The compound is now seeking funds for an efficacy study. It will in parallel be developed as a specials product and later be incorporated into new topical formulations (gel, patch, spray)</gtr:description><gtr:id>27E0AECE-7D44-4163-B649-B069BE096079</gtr:id><gtr:impact>This could bring revenue to the University and a spin out company and encourage other clinicians to think about IP that is contained within their studies.</gtr:impact><gtr:outcomeId>LNheZwkZZZ9</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>chronic pain treatment 3</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>ipSOX ltd</gtr:companyName><gtr:description>www.ipsox.co.uk
ipSOX covers for insulin pumps come in a selection of colours and designs that stretch to fit your insulin pump. All ipSOX profits are reinvested to support diabetes care.</gtr:description><gtr:id>ED549C84-8C21-448F-9A0C-0F32CEFCD853</gtr:id><gtr:impact>Provided over 20000 covers and is currently designing products for use in sporting activities.</gtr:impact><gtr:outcomeId>pojpPm5BzEc</gtr:outcomeId><gtr:url>http://www.ipsox.co.uk</gtr:url><gtr:yearCompanyFormed>2011</gtr:yearCompanyFormed></gtr:spinOutOutput><gtr:spinOutOutput><gtr:companyName>NeurocentRx Pharma</gtr:companyName><gtr:description>www.neurocentrx.com
The company is focussed on building a platform of products for treatment of chronic neuropathic pain and will be launched its first product as specials in 2015. The product is being supplied based on hospital request across the UK. The topical product uses menthol a natural agonist of TRPM8 that has been demonstrated in a 50 patient trial to be effective in cancer treatment induced neuropathic pain. NeurocentRx has licensed a University patent for the use of menthol in this indication that is now granted in Europe. 
NeurocentRx Pharma has also licensed the data from a large clinical trial on oral ketamine as will examine the data for potential support of a regulatory study when the study reports.</gtr:description><gtr:id>D25ECEFA-55DF-409A-8CF6-0738460E2526</gtr:id><gtr:impact>The company has raised over &amp;pound;500,000 seed investment and grants.</gtr:impact><gtr:outcomeId>UDoE8pVYkRB</gtr:outcomeId><gtr:url>http://www.neurocentrx.com/</gtr:url><gtr:yearCompanyFormed>2013</gtr:yearCompanyFormed></gtr:spinOutOutput><gtr:spinOutOutput><gtr:companyName>Fibromed Products Ltd</gtr:companyName><gtr:description>Company has been formed (fibromed.co.uk) with 3 leading accademics and HM. Biobank of phenotyped and genotyped cells for iPS development is under construction working with hospitals and Generation Scotland biobank. Hepatocytes are being validate by industry collaborations. http://www.fibromed.co.uk.
The company was wound up in 2015 due to failure to close investment round.</gtr:description><gtr:id>D709BD93-86ED-46EE-86F3-557744851426</gtr:id><gtr:impact>Agreements with Generation Scotland, Roslin Cells and University will underpin the growth of the company. 
Fibromed Product was formed from Fibromed Ltd launched in 2011. 
The companies hepatocyte system was described by Oliver Flint of BMS as the best available for testing hepatotoxic liabilities of drug molecules.</gtr:impact><gtr:outcomeId>fibmoHbCtdw</gtr:outcomeId><gtr:url>http://www.fibromed.co.uk/</gtr:url><gtr:yearCompanyFormed>2013</gtr:yearCompanyFormed></gtr:spinOutOutput><gtr:spinOutOutput><gtr:companyName>Aquila Biomedical Ltd</gtr:companyName><gtr:description>Aquila Biomedical is a research service company with strong links to the University. 
http://www.aquila-bm.com</gtr:description><gtr:id>32596D95-54DF-4C80-8BF2-E46A5F2ABD4C</gtr:id><gtr:impact>Company formed, 2 SMART awards received and 20 employees actively validating models in auto immune MS and pain with pharmaceutical contracts in place. Global client base US, EU and Japan Pharma and Biotech. 
Company now delivering immuno-oncology models for drug discovery. 
Formed an LLP Aquila Histoplex to provide advanced histology. SO304736. Due to success this LLP is now being incorporated as a division of Aquila
http://histoplex.co.uk/
Aquila is now trading profitably and is scheduled to be at 30 employees in early 2018.</gtr:impact><gtr:outcomeId>RPFTc1hFju8</gtr:outcomeId><gtr:url>http://www.aquila-bm.com/index.html</gtr:url><gtr:yearCompanyFormed>2011</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>BD8A7C70-2477-4E9F-97D1-6D603D85E936</gtr:id><gtr:title>Developing high-fidelity hepatotoxicity models from pluripotent stem cells.</gtr:title><gtr:parentPublicationTitle>Stem cells translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a52a5bf83bf13a7ced65f37d2f238f1"><gtr:id>5a52a5bf83bf13a7ced65f37d2f238f1</gtr:id><gtr:otherNames>Medine CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2157-6564</gtr:issn><gtr:outcomeId>pm_13602_22_23757504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E4C07A3-2D4B-423D-9609-3D3F94E80C8A</gtr:id><gtr:title>Stem Cells in Regenerative Medicine - Science, regulation and business strategies</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a58d69ad4f17dd544ce82aba3158212b"><gtr:id>a58d69ad4f17dd544ce82aba3158212b</gtr:id><gtr:otherNames>Cameron K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:isbn>978-1-119-97139-9</gtr:isbn><gtr:outcomeId>567807665fafc9.42072265</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700000</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>